N@N

Lpath, Inc.: Lpath to Provide Fourth Quarter 2008 Business Review and 2009 Plan

_{//health-fitness.news-articles.net/content/2009/ .. -quarter-2008-business-review-and-2009-plan.html}
^{Published in Health and Fitness on Wednesday, February 4th 2009 at 10:01 GMT, Last Modified on 2009-02-04 10:02:37 by Market Wire}  

SAN DIEGO, CA--(Marketwire - February 4, 2009) - Lpath, Inc. (OTCBB: [ LPTN ]) will host a teleconference on Wednesday, February 11 at 11:30am EST to provide a review of the fourth quarter 2008 and an outlook for 2009.

Lpath's chief executive officer, Scott Pancoast, will conduct the call. There will be a question-and-answer session directly following the presentation.

To participate in the teleconference, please call toll-free 877-407-9210 (direct dial 201-689-8049) five minutes before the scheduled start in order to register for the call. The call is also accessible on the Internet at [ http://www.investorcalendar.com/IC/CEPage.asp?ID=140640 ].

A replay of the call will be available three hours after the call's completion for seven days at 877-660-6853 (direct dial 201-612-7415). Account number 286 and conference ID number 312160 are both required for playback.

About Lpath

Lpath, Inc., headquartered in San Diego, is the category leader in bioactive-lipid-targeted therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP™, an antibody against Sphingosine-1-Phosphate (S1P), is currently in a Phase 1 clinical trial in cancer and also holds promise against multiple sclerosis and various other disorders. ASONEP is being developed with the support of partner Merck-Serono as part of a worldwide exclusive license. A second product candidate, iSONEP™ (the ocular formulation of the S1P antibody), has demonstrated superior results in various preclinical models of age-related macular degeneration (AMD) and retinopathy and is in a Phase 1 clinical trial in wet-AMD patients. Lpath's third product candidate, Lpathomab™, is an antibody against Lysophosphatidic Acid (LPA), a key bioactive lipid that has been long recognized as a valid disease target (cancer, neuropathic pain, fibrosis). The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2™ drug-discovery engine, which the company is leveraging as a means to expand its pipeline. Please visit [ www.Lpath.com ].